Effects of alternate-day fasting on body weight and dyslipidaemia in patients with non-alcoholic fatty liver disease: a randomised controlled trial
Effects of alternate-day fasting on body weight and dyslipidaemia in patients with non-alcoholic fatty liver disease: a randomised controlled trial
复制标题
DOI：
10.1186/s12876-019-1132-8
复制
发表时间：
2019-12-18
影响因子：
2.4
通讯作者：
Chen, Zhi-Yuan
中科院分区：
文献类型：
--
作者：
Cai, Hua;Qin, Yue-Lan;Chen, Zhi-Yuan
背景：隔日禁食（ADF）是一种新的饮食疗法，可以减少体重和改善血脂异常，但这种饮食对非酒精性脂肪性肝病（NAFLD）患者的影响尚不清楚。本研究的目的是评估ADF对NAFLD患者体重和血脂的影响。方法：将271例NAFLD患者随机分为ADF组、限时喂养组（TRF）和对照组，分别给予12周的饮食。进行人体测量（体重、脂肪质量/无脂肪质量），并酶分析血浆脂质。结果：4周内，与对照组相比，ADF组体重下降4.56 +/- 0.41 kg (6.1 +/- 0.5%)， TRF组体重下降3.62 +/- 0.65 kg (4.83 +/- 0.9%) (P < 0.001)， 12周后两组体重下降幅度更大（ADF: - 4.04 +/- 0.54 kg, 5.4 +/- 0.7%; TRF: - 3.25 +/- 0.67 kg, 4.3 +/- 0.9%）。ADF （- 3.49 +/- 0.37 kg; 11 +/- 1.2%）和TRF （- 2.91 +/- 0.41 kg; 9.6 +/- 1.3%）显著降低了脂肪质量，ADF在12周后进一步降低了脂肪质量（- 3.48 +/- 0.38 kg; 11 +/- 1.2%）。与对照组和TRF组相比，ADF组在两个时间点的总胆固醇均显著降低（- 0.91 +/- 0.07 mmol/L; 18.5 +/- 1.5%）。ADF （- 0.64 +/- 0.06 mmol/L, 25 +/- 1.9%）和TRF （0.58 +/- 0.07 mmol/L, 20 +/- 1.7%）在12周后均显著降低了血清甘油三酯（P < 0.001）。无脂量、高密度脂蛋白、低密度脂蛋白、空腹胰岛素、葡萄糖、肝脏硬度、收缩压或舒张压的变化在两组之间没有差异。结论：ADF对于NAFLD患者是一种有效的饮食疗法，可以在相对较短的时间内（4 - 12周）实现体重减轻和血脂异常的改善。ADF对心血管疾病的潜在预防作用有待进一步研究证实。
Background: Alternate-day fasting (ADF) is a novel diet therapy that may achieve reduction in body weight and improvement of dyslipidaemia, but the impact of this diet on patients with non-alcoholic fatty liver disease (NAFLD) remains unknown. The aim of this study was to evaluate the effects of ADF on the body weight and lipid profile of individuals with NAFLD.Methods: NAFLD patients (n = 271) were randomised to the ADF group, time-restricted feeding (TRF) group, or the control group and subjected to the respective diet for 12 weeks. Anthropometric measurements (body weight, fat mass/fat-free mass) were performed, and plasma lipids were analysed enzymatically.Results: Within 4 weeks, the body weight decreased significantly (P < 0.001) in the ADF group by 4.56 +/- 0.41 kg (6.1 +/- 0.5%) and the TRF group by 3.62 +/- 0.65 kg (4.83 +/- 0.9%) compared to the control group, and it decreased even more after 12 weeks in both groups (ADF: - 4.04 +/- 0.54 kg, 5.4 +/- 0.7%; TRF: - 3.25 +/- 0.67 kg, 4.3 +/- 0.9%). Fat mass was significantly reduced by ADF (- 3.49 +/- 0.37 kg; 11 +/- 1.2%) and TRF (- 2.91 +/- 0.41 kg; 9.6 +/- 1.3%), with ADF leading to a further reduction in fat mass after 12 weeks (- 3.48 +/- 0.38 kg; 11 +/- 1.2%). Total cholesterol was significantly decreased at both time points in the ADF group (- 0.91 +/- 0.07 mmol/L; 18.5 +/- 1.5%) compared to the control and TRF groups. Both ADF (- 0.64 +/- 0.06 mmol/L; 25 +/- 1.9%) and TRF (0.58 +/- 0.07 mmol/L; 20 +/- 1.7%) achieved a significant reduction in serum triglycerides (P < 0.001) after 12 weeks. Changes in fat free mass, HDL, LDL, fasting insulin, glucose, liver stiffness, and systolic or diastolic blood pressure did not differ between the groups.Conclusions: ADF appears to be an effective diet therapy for individuals with NAFLD that can achieve weight loss and improvement of dyslipidaemia within a relatively short period of time (4 to 12 weeks). Potential preventive effects of ADF on cardiovascular disease need to be confirmed by future investigations.